We speculate that given the abundance of tumor-associated macrophages and the characteristic immunosuppressive microenvironment of GBM, altering MTA-mediated purinergic signaling has the potential to significantly impact tumor growth and augment immunotherapeutic interventions in MTAP-deleted GBM. This evidence concerns the gene MTAP and glioblastoma.